THE EFFECT OF TRANSDERMAL 17-BETA-ESTRADIOL ON GLUCOSE-METABOLISM OF POSTMENOPAUSAL WOMEN IS EVIDENT DURING THE ORAL BUT NOT THE INTRAVENOUS GLUCOSE-ADMINISTRATION
A. Cagnacci et al., THE EFFECT OF TRANSDERMAL 17-BETA-ESTRADIOL ON GLUCOSE-METABOLISM OF POSTMENOPAUSAL WOMEN IS EVIDENT DURING THE ORAL BUT NOT THE INTRAVENOUS GLUCOSE-ADMINISTRATION, Maturitas, 28(2), 1997, pp. 163-167
Objectives: To evaluate the effect of transdermal 17-beta-estradiol (5
0 mu g/day) on glucose metabolism of postmenopausal women. Study desig
n: A frequently sampled intravenous glucose tolerance test (FSIGT), to
calculate insulin sensitivity (S-I) and peripheral glucose utilizatio
n independent of insulin (S-G), and an oral glucose tolerance test (75
g; OGTT), were performed in nine postmenopausal women prior to, and a
fter 2 months of, treatment. Results: Estradiol decreased insulin and
increased the C-peptide/insulin ratio both during fasting (P < 0.02) a
nd OGTT (insulin levels, P < 0.01; C-peptide/insulin ratio, P < 0.05),
but not FSIGT. Glucose levels, C-peptide levels, S-I and S-G were not
affected. Conclusions: In spite of unmodified S-I, the reduction of i
nsulin levels and the increase of the C-peptide/insulin ratio, observe
d during fasting and OGTT, support a beneficial effect of estradiol on
glucose metabolism. This effect probably requires the interplay of es
tradiol with gastrointestinal factors. (C) 1997 Elsevier Science Irela
nd Ltd.